Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
LG-631 by Lentigen Technology for Gliosarcoma: Likelihood of Approval
LG-631 is under clinical development by Lentigen Technology and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II...
Data Insights
LG-631 by Lentigen Technology for Glioblastoma Multiforme (GBM): Likelihood of Approval
LG-631 is under clinical development by Lentigen Technology and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...